Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50

ADC Therapeutics SA (NYSE:ADCT) has earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $7.50.

Several research firms have recently commented on ADCT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. HC Wainwright decreased their price objective on ADC Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim reiterated a “buy” rating and set a $10.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, November 12th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $5.00 target price on shares of ADC Therapeutics in a research note on Wednesday, December 3rd.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ADCT. ProShare Advisors LLC increased its stake in ADC Therapeutics by 27.0% in the 4th quarter. ProShare Advisors LLC now owns 15,727 shares of the company’s stock worth $56,000 after buying an additional 3,339 shares in the last quarter. R Squared Ltd purchased a new stake in shares of ADC Therapeutics during the third quarter worth about $59,000. Henrickson Nauta Wealth Advisors Inc. bought a new stake in ADC Therapeutics during the 4th quarter valued at approximately $69,000. SG Americas Securities LLC bought a new stake in ADC Therapeutics during the 4th quarter valued at approximately $86,000. Finally, Creative Planning purchased a new position in ADC Therapeutics in the 2nd quarter worth approximately $96,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Stock Performance

Shares of NYSE:ADCT opened at $3.98 on Friday. The stock’s 50-day simple moving average is $3.72 and its two-hundred day simple moving average is $3.69. The stock has a market capitalization of $493.04 million, a price-to-earnings ratio of -2.74 and a beta of 1.93. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.80.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. The business had revenue of $16.43 million during the quarter, compared to the consensus estimate of $17.08 million. As a group, equities analysts forecast that ADC Therapeutics will post -1.69 earnings per share for the current fiscal year.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.